Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Juni 2017 10:35 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event

MISSION VIEJO, CA--(Marketwired - June 08, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and...
15. Mai 2017 17:00 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017

MISSION VIEJO, CA--(Marketwired - May 15, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and...
15. März 2017 09:00 ET | Quelle: Aeolus Pharmaceuticals

AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis

MISSION VIEJO, CA--(Marketwired - March 15, 2017) - TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE BLOOD CELLS, MACROPHAGES AND LYMPHOCYTESDETAILED...
22. Februar 2017 15:13 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers

MISSION VIEJO, CA--(Marketwired - February 22, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
21. Dezember 2016 08:00 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Announces Fiscal Year 2016 Financial Results

MISSION VIEJO, CA--(Marketwired - December 21, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
19. September 2016 09:19 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"

MISSION VIEJO, CA--(Marketwired - September 19, 2016) - TREATMENT WITH AEOL 10150 AFTER EXPOSURE TO SULFUR MUSTARD GAS --IMPROVED SURVIVAL AT 48 HOURS AFTER EXPOSURE FROM 36 PERCENT TO 88...
06. September 2016 08:30 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure Against Sulfur Mustard Gas

MISSION VIEJO, CA--(Marketwired - September 06, 2016) - AEOL 10150 DOUBLED SURVIVAL AT 28 DAYS AFTER EXPOSURE TO LETHAL SULFUR MUSTARD GASMEDIAN SURVIVAL TIME FOR ANIMALS TREATED WITH AEOL 10150 WAS...
31. August 2016 09:09 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016

MISSION VIEJO, CA--(Marketwired - August 31, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
15. August 2016 16:29 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results

MISSION VIEJO, CA--(Marketwired - August 15, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
23. Mai 2016 08:00 ET | Quelle: Aeolus Pharmaceuticals

Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference

MISSION VIEJO, CA--(Marketwired - May 23, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation,...

Nächste Seite